Preclinical studies have demonstrated that antibiotic treatment induces gut dysbiosis-marked by reduced alpha diversity, a decreased Firmicutes/Bacteroidetes ratio, depletion of beneficial genera, and enrichment of pro-inflammatory taxa (Tejkalov et al., 2023
Research reveals that BPC-157 may also speed up healing in the gastrointestinal tract including anastomosis in rats after gastrointestinal surgeries such as esophageal anastomosis, and intestinal fistulas in rat models of inflammatory bowel disease
Rewired glutathione metabolism in aged mouse kidney tissue
Basic, one-size-fits-all programs
-2.1% in the placebo group) at 48 weeks, the highest pharmacologic weight loss reported to date [24]
About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases